Melvin Reichman

Research interests include: neuroscience, understanding how protein misfolding leads to neurodegeneration in amyotrophic lateral sclerosis (ALS) and discovering combination-drug treatment; diabetes, applying high throughput screening to discover fructosamine-3-kinase inhibitors to treat diabetes complications; drug discovery, developing and applying new screening technologies to discover novel combination drugs; public-private partnering in pharmaceutical research and development, a unique open innovation model called Double Blinded Drug Discovery®.